Liquidity & Technicals

Liquidity & Technicals — Supreme PLC (SUP.L)

The liquidity verdict is specialist-only: even at an aggressive 20% ADV participation rate, a fund can only execute about £189k of stock over a five-day window, which caps the practical implementable position at well under one percent of any meaningful AUM. The tape itself is constructive on near-term momentum (RSI riding 70, MACD histogram positive and accelerating) but trapped under a still-falling 200-day average, leaving the stock in a counter-trend bounce within a broken longer-term setup.

1. Portfolio implementation verdict

The stance score nets to about minus one: trend (price under a falling 200d), relative strength, and volume regime are unconstructive; momentum and the recent 50/200 dynamic are short-term constructive; volatility and 52-week position are neutral. The technical message and the liquidity message point in the same direction — wait or build slowly.

2. Price snapshot strip

Beta is shown as a proxy because no formal benchmark regression is computed in the data pack; for an AIM consumer-staples distributor the realised co-movement with the broad UK index is structurally low and noisy. The 52-week percentile of 44 says the stock is essentially mid-range — neither breaking out nor breaking down — and the YTD profile is a round-trip rather than a directional move.

3. The critical chart — full-history price with 50/200-day moving averages

The current 160p close sits 0.7% below the 200-day SMA of 161.1p — formally below trend, but within the no-man's-land band and not far from a reclaim. The 50-day at 141.3p is rising sharply off the February 2026 low, confirming the near-term bounce, but is still well under the 200-day, so the longer regime remains a sideways-to-down channel between roughly 124p and 205p with no demonstrated breakout in either direction. The five-year frame (2021 IPO debut at 150p, ATH 245p in mid-2021, ATL 72.5p in September 2023) shows two distinct regimes separated by the 2022–2023 derate, with current price still well below the cycle high.

4. Relative strength versus the broad market

What the rebased line does show: Supreme rallied roughly 60% from the May-2023 base to mid-2025, gave back most of the gain into early 2026, and is now back to a 54% cumulative return over three years — well behind the rebased mid-2025 peak. Against UK consumer staples broadly, that profile has been a laggard since the second half of 2025; the absence of a benchmark line means the magnitude of the relative drag is qualitative rather than quantified.

5. Momentum panel — RSI(14) and MACD histogram

RSI(14) is at 70.7, sitting right on the conventional overbought line after a clean V-shape from 19 in early February. MACD histogram has crossed firmly positive (latest +1.87 after a print of +4.09 mid-rally) and is rolling slightly off its peak — the standard pattern of a momentum impulse fading at the second derivative even as the first derivative remains constructive. Net read for the next one to three months: short-term momentum is bullish but no longer fresh; a single weak session could put RSI back in the 60s and the histogram into deceleration. There is no bearish divergence in the immediate window — price highs and oscillator highs tracked together — but neither is there confirmation that this is the start of a new bull leg rather than a relief rally.

6. Volume, volatility and sponsorship

The five most recent unusual-volume sessions cluster on red rather than green days — the November 2025 flush at 156p and the February 2026 print at 148p both came on 14× and 11× normal volume, which is the print pattern of forced selling more than fundamental re-rating. The single notable up-day spike was the July 2025 push to 190p on roughly 10× volume, and that level has since been ceded. Tape sponsorship is therefore mixed: there are buyers, but they have not yet absorbed the most recent supply.

The current realised vol of 37.1% sits essentially on the five-year median (37.7%) and well inside the p20–p80 normal band of 27.9% to 52.0%. The ATR(14) of 2.5p on a 160p stock is roughly a 1.6% daily true range, consistent with the 0.91% median 60-day intraday range — the tape is moving, but it is not stressed by historical standards and is not pricing a binary catalyst. Compression below the p20 line of 27.9% would historically have preceded directional moves; current vol is not yet at that compressed regime.

7. Institutional liquidity panel

A. ADV and turnover

ADV 60d is materially higher than ADV 20d (212k vs 118k), reflecting the volume cluster around the late-2025 sell-off; the 20-day figure is the more conservative and the more relevant for a build today. Annual turnover of 38% — one in roughly 2.6 years — confirms a stock dominated by long-term holders and management/family control rather than active institutional rotation.

B. Fund-capacity table

This is the table that decides the conversation. Even at 20% ADV — already an aggressive participation rate for AIM — a five-day build clears just £189k. A 5% portfolio weight is therefore only viable for funds under roughly £3.8m, and a 2% weight for funds under £9.5m. Anything resembling a UK small-cap fund (£50m+) is capacity-constrained out of any meaningful single-week entry.

C. Liquidation runway

A 1% issuer-level holding takes roughly two and a half months to liquidate at 20% ADV and over four months at 10% ADV. There is no scenario in this table where a fund with a meaningful percent-of-issuer position can reduce risk inside a single quarter without moving the print materially.

D. Price-range proxy

The median 60-day intraday range is 0.91%, which is inside the 2% threshold above which intraday impact cost becomes a separate concern. Friction here is the absolute size of ADV, not the bid-ask or daily range — the stock trades cleanly when it trades, but it does not trade enough.

Verdict. The largest size that genuinely clears a five-day build at 20% ADV is roughly £190k of stock, equivalent to under 0.1% of issuer market cap; at the more conservative 10% ADV cap, that drops to around £95k. A fund that wants real exposure must accept either a multi-week patient build via crossings and ADV-paced algos, or a sourced block from a long-term holder.

8. Support / resistance map and technical scorecard

Stance — neutral on a 3-to-6 month horizon

The setup is a counter-trend bounce inside a broken longer-term picture. Momentum says higher, trend says lower, volume says supply has not been cleared, and liquidity says it does not matter for institutional sizing because the stock cannot absorb meaningful order flow. The bullish case requires a decisive close above 175p — that reclaims the Bollinger upper band, the July 2025 high-volume cap, and forces the 200-day to stop falling. The bearish case re-asserts itself on a close below 141p — a clean break of the 50-day SMA from above with the death cross still in place would re-open 124p as the obvious target and 116p as the volatility-band floor.

Liquidity is the constraint. The correct action for any fund larger than roughly £10m of AUM is watchlist only; for specialist UK small-cap mandates that can stomach multi-week building, the entry strategy is patient, ADV-paced accumulation between 141p (50-day support) and 160p (spot), with an explicit pre-trade understanding that a 1% issuer position will take a quarter or more to unwind if the thesis breaks.

The most-recent technical setups for an investor sizing a position: (1) the November 2025 death cross is the dominant medium-term signal and has not been invalidated; (2) the February 2026 capitulation low at 124p, printed on 11× volume, is the line in the sand for the bear case; (3) the current RSI/MACD impulse is a counter-trend rally to be sold into, not bought into, until 175p clears; (4) a tightening daily range (ATR roughly 2.5p) inside the 124–175p envelope is the early-warning trigger for the next directional move; (5) ADV remains the binding constraint on any institutional sizing decision regardless of which way the next signal breaks.